Aimmune Therapeutics Inc., which is seeking FDA approval for a peanut allergy treatment, has been operating out of a Silicon Valley office in California, but has now made public that they’ve signed a lease for a manufacturing space in Florida.
The lease is for about 20,000 square feet of manufacturing space in a facility in Clearwater, Florida. The lease was revealed in financial disclosure filings with the U.S. Securities and Exchange Commission.
Phase 3 clinical trials and preparation for manufacture are underway.
Aimmune is obviously expecting their upcoming Phase 3 trails to be successful and to lead to fast-track approval by the Food and Drug Administration for their peanut allergy treatment. The lease for the manufacturing space is slated to begin in September and expires in 2025.
The company has not commented on what the space is for, but given the type of facility and the upcoming trials, it can be assumed that the Florida space will be used to make their product at scale. Aimmune recently raised $160 million in an initial public offering (IPO) on NASDAQ.
Disclosure: The author and this site have no financial ties to Aimmune Therapeutics.